COVID-19 And M&A: Multiple Scenarios In Store As World Adapts

Risks And Opportunities Emerging

The coronavirus pandemic could dull pharma M&A activity in the short-term as companies hoard cash and prioritize core activities. But experts say stress in the system could potentially push some firms to cull surplus assets or seek financial/strategic investors, amid a generally tough funding environment. Private equity investors may also find attractive investment opportunities to pursue.

COVID-19 Could Dull M&A But Systemic Stress Could Also Trigger Transactions • Source: Shutterstock

The coronavirus pandemic has battered businesses across sectors, including pharma. Supply chain disruptions, pain on the logistics front and commercialization challenges are all playing out across geographies.

The resultant general strains in the system and a tough funding environment, compounded by high leverage at some smaller drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

13 Jun 2025

• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

13 Jun 2025

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.